Biotech & FDA Trader

This is a template.
The default signal is keyword discovery + FDA PDUFA calendar alignment — remix it with ClinicalTrials.gov API for trial status, BioMedTracker historical approval rates by indication, or biotech earnings call sentiment analysis.
The skill handles all the plumbing (market discovery, trade execution, safeguards). Your agent provides the alpha.

Strategy Overview

The global biotech market is valued at $1.77 trillion (2025) and growing to $6.34 trillion by 2035 (13.6% CAGR). Biotech prediction markets have some of the highest information density — FDA decisions are binary, have clear dates (PDUFA), and are well-studied. This skill trades:

• FDA approvals — Breakthrough therapy designations, CRISPR/oncology approvals, GLP-1 next-gen
• Clinical trials — Phase 3 outcomes, trial enrollment milestones
• Biotech IPOs — Class of 2026 IPO announcement and performance markets
• Pharma M&A — Large-cap acquisition deals in oncology, AI drug discovery
• Precision medicine — CAR-T, mRNA vaccine, liquid biopsy milestones

Key insight: FDA approval rates by indication are well-documented. When Polymarket prices deviate significantly from historical base rates, there's tradeable edge.

Signal Logic